DOCSLIB.ORG

Get High-Res Image

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Get High-Res Image 52 29 37 29 32 69 69 78 25 20 15 10 5 # mutations Non syn. Syn. A->T C->(A/T) A->(C/G) C->G indel+null double_null # mutations/Mb 0 1% 2% 1% 2% 1% 1% 1% 1% 2% 1% 1% 2% 2% 1% 1% 1% 2% 1% 1% 1% 2% 2% 1% 2% 1% 3% 1% 1% 2% 2% 1% 2% 2% 2% 1% 1% 2% 1% 2% 1% 1% 1% 2% 4% 3% 2% 2% 1% 1% 2% 2% 1% 1% 2% 2% 1% 2% 2% 2% 2% 2% 1% 3% 2% 6% 3% 2% 1% 2% 2% 3% 2% 2% 3% 2% 2% 2% 2% 2% 2% 2% 2% 2% 6% 2% 2% 2% 12% 2% 2% 3% 2% 2% 3% 2% 7% 2% 2% 3% 5% 3% 8% 3% 4% 3% 8% 3% 9% 9% 5% 9% 7% 11% 23% 20% 21% 0 1 2 3 4 GBM-06-0743-TP GBM-02-0003-TP GBM-32-1970-TP GBM-19-2625-TP GBM-06-2563-TP GBM-06-2567-TP GBM-06-0876-TP GBM-14-0813-TP GBM-28-5207-TP GBM-32-1991-TP GBM-76-4927-TP GBM-06-0157-TP GBM-06-0155-TP GBM-06-0649-TP GBM-06-0749-TP GBM-14-1395-TP GBM-76-6191-TP GBM-28-5209-TP GBM-06-2561-TP GBM-06-1804-TP GBM-06-0881-TP GBM-76-6661-TP GBM-14-1456-TP GBM-14-0790-TP GBM-06-6695-TP GBM-76-6656-TP GBM-26-5139-TP GBM-06-0750-TP GBM-81-5911-TP GBM-14-1034-TP GBM-27-2528-TP GBM-06-5413-TP GBM-06-0879-TP GBM-15-0742-TP GBM-19-1790-TP GBM-06-0154-TP GBM-06-0158-TP GBM-06-0211-TP GBM-76-4926-TP GBM-28-1747-TP GBM-06-0137-TP GBM-06-0650-TP GBM-06-0142-TP GBM-14-1829-TP GBM-06-2557-TP GBM-14-1823-TP GBM-12-3652-TP GBM-14-0786-TP GBM-06-5856-TP GBM-06-0174-TP GBM-27-1831-TP GBM-81-5910-TP GBM-12-3650-TP GBM-14-0789-TP GBM-06-0747-TP GBM-06-6700-TP GBM-19-2624-TP GBM-06-0878-TP GBM-16-1045-TP GBM-06-2565-TP GBM-76-6662-TP GBM-32-2634-TP GBM-06-0184-TP GBM-76-6286-TP GBM-06-5858-TP GBM-76-6283-TP GBM-27-1838-TP GBM-06-0875-TP GBM-06-0195-TP GBM-27-2519-TP GBM-76-4925-TP GBM-16-0846-TP GBM-76-6664-TP GBM-19-2629-TP GBM-06-0128-TP GBM-15-1444-TP GBM-76-4929-TP GBM-74-6573-TP GBM-06-6698-TP GBM-76-6663-TP GBM-32-2491-TP GBM-06-0130-TP GBM-06-2569-TP GBM-26-5133-TP GBM-06-5417-TP GBM-06-0221-TP GBM-32-4208-TP GBM-27-2521-TP GBM-14-4157-TP GBM-26-1442-TP GBM-41-5651-TP GBM-06-2559-TP GBM-06-0238-TP GBM-02-2485-TP GBM-76-6193-TP GBM-06-6694-TP GBM-41-2575-TP GBM-06-2558-TP GBM-06-0744-TP GBM-28-5219-TP GBM-32-4210-TP GBM-27-1836-TP GBM-12-0619-TP GBM-06-0237-TP GBM-06-0189-TP GBM-14-0817-TP GBM-28-5216-TP GBM-26-5136-TP GBM-14-0871-TP GBM-14-1825-TP GBM-06-0190-TP GBM-76-6657-TP GBM-26-6174-TP GBM-19-5955-TP GBM-32-4213-TP GBM-06-0192-TP GBM-41-4097-TP GBM-06-5412-TP GBM-06-0939-TP GBM-32-5222-TP GBM-12-1597-TP GBM-12-0618-TP GBM-06-0166-TP GBM-76-4931-TP GBM-06-0124-TP GBM-16-0861-TP GBM-28-2510-TP GBM-27-1834-TP GBM-06-0216-TP GBM-06-0188-TP GBM-06-0644-TP GBM-76-6192-TP GBM-06-5418-TP GBM-27-1837-TP GBM-28-1753-TP GBM-19-5952-TP GBM-06-0125-TP GBM-02-2470-TP GBM-41-2573-TP GBM-76-4934-TP GBM-32-1977-TP GBM-76-4935-TP GBM-06-0168-TP GBM-02-0055-TP GBM-26-5132-TP GBM-19-5959-TP GBM-74-6577-TP GBM-32-1982-TP GBM-41-2571-TP GBM-06-0882-TP GBM-74-6575-TP GBM-06-2562-TP GBM-06-0129-TP GBM-19-5947-TP GBM-06-0877-TP GBM-28-2513-TP GBM-76-6280-TP GBM-06-6388-TP GBM-41-3915-TP GBM-19-5951-TP GBM-12-0688-TP GBM-02-0033-TP GBM-32-2632-TP GBM-19-2623-TP GBM-06-0213-TP GBM-06-0140-TP GBM-27-2524-TP GBM-06-0214-TP GBM-06-5410-TP GBM-41-3392-TP GBM-14-1043-TP GBM-06-0119-TP GBM-28-6450-TP GBM-28-2502-TP GBM-19-5953-TP GBM-32-1986-TP GBM-41-6646-TP GBM-32-1980-TP GBM-28-5208-TP GBM-32-2494-TP GBM-06-2570-TP GBM-02-2483-TP GBM-06-6389-TP GBM-06-6701-TP GBM-06-6391-TP GBM-06-0210-TP GBM-27-1835-TP GBM-32-4211-TP GBM-06-0185-TP GBM-26-5135-TP GBM-28-5213-TP GBM-19-5954-TP GBM-02-0047-TP GBM-12-5301-TP GBM-41-2572-TP GBM-06-0171-TP GBM-74-6578-TP GBM-32-1979-TP GBM-16-1048-TP GBM-27-2527-TP GBM-06-5414-TP GBM-06-6390-TP GBM-27-2526-TP GBM-19-2620-TP GBM-02-2486-TP GBM-06-5411-TP GBM-28-5211-TP GBM-76-4928-TP GBM-12-0615-TP GBM-28-5214-TP GBM-06-0152-TP GBM-06-5408-TP GBM-06-5415-TP GBM-76-6282-TP GBM-06-0173-TP GBM-12-3649-TP GBM-06-6697-TP GBM-26-5134-TP GBM-14-0781-TP GBM-28-2501-TP GBM-06-0169-TP GBM-06-6699-TP GBM-06-0122-TP GBM-19-2619-TP GBM-28-2514-TP GBM-26-1439-TP GBM-19-5960-TP GBM-06-0646-TP GBM-26-6173-TP GBM-06-0240-TP GBM-06-0145-TP GBM-14-0787-TP GBM-14-0862-TP GBM-32-4209-TP GBM-06-0141-TP GBM-28-5204-TP GBM-19-1390-TP GBM-19-2631-TP GBM-06-0686-TP GBM-41-3393-TP GBM-12-5295-TP GBM-06-0209-TP GBM-14-0740-TP GBM-12-0821-TP GBM-76-6660-TP GBM-27-2523-TP GBM-28-5218-TP GBM-12-0692-TP GBM-14-2554-TP GBM-28-2509-TP GBM-27-1830-TP GBM-32-2495-TP GBM-14-1450-TP GBM-12-3653-TP GBM-06-0745-TP GBM-76-4932-TP GBM-06-5859-TP GBM-06-0151-TP GBM-06-0126-TP GBM-19-4068-TP GBM-06-0645-TP GBM-32-2615-TP GBM-28-5220-TP GBM-06-6693-TP GBM-06-0648-TP GBM-28-5215-TP GBM-06-0241-TP GBM-27-1832-TP GBM-32-2498-TP GBM-12-0616-TP GBM-87-5896-TP GBM-19-5950-TP GBM-06-0219-TP GBM-27-2518-TP GBM-06-0167-TP GBM-27-1833-TP GBM-14-3476-TP GBM-32-2638-TP GBM-06-2564-TP GBM-76-6285-TP GBM-19-5958-TP GBM-74-6584-TP GBM-12-5299-TP GBM-32-4719-TP GBM-06-1806-TP GBM-06-0132-TP GBM-28-2499-TP GBM-08-0386-TP GBM-06-0165-TP GBM-06-0139-TP GBM-06-0178-TP "OM121L12 $(!T1H2BE ADAMTS16 TMEM229B $EATR7B2 !ER"(%B4 DCA)12L2 .B! R17 Nonsense Splice site Missense Syn. TMPR!!6 NT%AP2 !LC#6A1 &GT2B28 TAS2R41 !ULT1B1 0 20 40 60 80 100 0 20 40 60 80 100 MAGEB4 "DG)RA GABRB2 "CD$A1 "CD$A3 GABRA1 DK%2C "RO'R2 GABRA6 !EMA3C #R5AR1 "OD%L1 #R52M1 TREML2 ADAM29 "CD$19 !PR,D5 #R5D16 "LC*D3 ,"3A5 OL6A3 'DELC2 #R13C5 LRR 55 OL1A2 #R5D18 &GT2A3 #R5D13 GLT1D1 !LC1A6 ALP"L2 #R5.2 "('3CA "OTE$ #R5M3 !EMG1 $MC%1 D# '5 "('3R1 ADC,5 AL R )#*R2 GNAT3 #R4D5 M& 16 M& 17 )#*G1 RBM47 DH18 #R5A1 TRP/6 !TAG2 ABCB1 AL%1 AZG"1 DC27 #R8'3 T!$+2 D""10 ELTD1 TRAT1 LRF%5 AP3!1 !PTA1 TPTE2 RIMS2 LZTR1 B #R 'LF17 GRM3 % .%T2 '()2B EGFR T $$ TGFA %#*4 A%#9 )GD5 "SG1 'PR" DRD5 DSG3 $ %1 "!"$ "TE% "CL# RYR2 "AN3 MSL3 "RB2 'LK6 RPL5 TP53 ID$1 LUM AFM REN )LG 'EL A1161ic %F1 RB1 -'( fraction 0.5 2.0 3.5 -log10(405alue) Other non syn. In frame in@61 Frame shift.
Load more

Recommended publications
  • Genetic Variation Across the Human Olfactory Receptor Repertoire Alters Odor Perception
    bioRxiv preprint doi: https://doi.org/10.1101/212431; this version posted November 1, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Genetic variation across the human olfactory receptor repertoire alters odor perception Casey Trimmer1,*, Andreas Keller2, Nicolle R. Murphy1, Lindsey L. Snyder1, Jason R. Willer3, Maira Nagai4,5, Nicholas Katsanis3, Leslie B. Vosshall2,6,7, Hiroaki Matsunami4,8, and Joel D. Mainland1,9 1Monell Chemical Senses Center, Philadelphia, Pennsylvania, USA 2Laboratory of Neurogenetics and Behavior, The Rockefeller University, New York, New York, USA 3Center for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, USA 4Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA 5Department of Biochemistry, University of Sao Paulo, Sao Paulo, Brazil 6Howard Hughes Medical Institute, New York, New York, USA 7Kavli Neural Systems Institute, New York, New York, USA 8Department of Neurobiology and Duke Institute for Brain Sciences, Duke University Medical Center, Durham, North Carolina, USA 9Department of Neuroscience, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA *[email protected] ABSTRACT The human olfactory receptor repertoire is characterized by an abundance of genetic variation that affects receptor response, but the perceptual effects of this variation are unclear. To address this issue, we sequenced the OR repertoire in 332 individuals and examined the relationship between genetic variation and 276 olfactory phenotypes, including the perceived intensity and pleasantness of 68 odorants at two concentrations, detection thresholds of three odorants, and general olfactory acuity.
    [Show full text]
  • Identification of 42 Genes Linked to Stage II Colorectal Cancer Metastatic Relapse
    Int. J. Mol. Sci. 2016, 17, 598; doi:10.3390/ijms17040598 S1 of S16 Supplementary Materials: Identification of 42 Genes Linked to Stage II Colorectal Cancer Metastatic Relapse Rabeah A. Al-Temaimi, Tuan Zea Tan, Makia J. Marafie, Jean Paul Thiery, Philip Quirke and Fahd Al-Mulla Figure S1. Cont. Int. J. Mol. Sci. 2016, 17, 598; doi:10.3390/ijms17040598 S2 of S16 Figure S1. Mean expression levels of fourteen genes of significant association with CRC DFS and OS that are differentially expressed in normal colon compared to CRC tissues. Each dot represents a sample. Table S1. Copy number aberrations associated with poor disease-free survival and metastasis in early stage II CRC as predicted by STAC and SPPS combined methodologies with resident gene symbols. CN stands for copy number, whereas CNV is copy number variation. Region Cytoband % of CNV Count of Region Event Gene Symbols Length Location Overlap Genes chr1:113,025,076–113,199,133 174,057 p13.2 CN Loss 0.0 2 AKR7A2P1, SLC16A1 chr1:141,465,960–141,822,265 356,305 q12–q21.1 CN Gain 95.9 1 SRGAP2B MIR5087, LOC10013000 0, FLJ39739, LOC10028679 3, PPIAL4G, PPIAL4A, NBPF14, chr1:144,911,564–146,242,907 1,331,343 q21.1 CN Gain 99.6 16 NBPF15, NBPF16, PPIAL4E, NBPF16, PPIAL4D, PPIAL4F, LOC645166, LOC388692, FCGR1C chr1:177,209,428–177,226,812 17,384 q25.3 CN Gain 0.0 0 chr1:197,652,888–197,676,831 23,943 q32.1 CN Gain 0.0 1 KIF21B chr1:201,015,278–201,033,308 18,030 q32.1 CN Gain 0.0 1 PLEKHA6 chr1:201,289,154–201,298,247 9093 q32.1 CN Gain 0.0 0 chr1:216,820,186–217,043,421 223,235 q41 CN
    [Show full text]
  • WO 2019/068007 Al Figure 2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/068007 Al 04 April 2019 (04.04.2019) W 1P O PCT (51) International Patent Classification: (72) Inventors; and C12N 15/10 (2006.01) C07K 16/28 (2006.01) (71) Applicants: GROSS, Gideon [EVIL]; IE-1-5 Address C12N 5/10 (2006.0 1) C12Q 1/6809 (20 18.0 1) M.P. Korazim, 1292200 Moshav Almagor (IL). GIBSON, C07K 14/705 (2006.01) A61P 35/00 (2006.01) Will [US/US]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., C07K 14/725 (2006.01) P.O. Box 4044, 7403635 Ness Ziona (TL). DAHARY, Dvir [EilL]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., P.O. (21) International Application Number: Box 4044, 7403635 Ness Ziona (IL). BEIMAN, Merav PCT/US2018/053583 [EilL]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., P.O. (22) International Filing Date: Box 4044, 7403635 Ness Ziona (E.). 28 September 2018 (28.09.2018) (74) Agent: MACDOUGALL, Christina, A. et al; Morgan, (25) Filing Language: English Lewis & Bockius LLP, One Market, Spear Tower, SanFran- cisco, CA 94105 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/564,454 28 September 2017 (28.09.2017) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/649,429 28 March 2018 (28.03.2018) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (71) Applicant: IMMP ACT-BIO LTD.
    [Show full text]
  • Strand Breaks for P53 Exon 6 and 8 Among Different Time Course of Folate Depletion Or Repletion in the Rectosigmoid Mucosa
    SUPPLEMENTAL FIGURE COLON p53 EXONIC STRAND BREAKS DURING FOLATE DEPLETION-REPLETION INTERVENTION Supplemental Figure Legend Strand breaks for p53 exon 6 and 8 among different time course of folate depletion or repletion in the rectosigmoid mucosa. The input of DNA was controlled by GAPDH. The data is shown as ΔCt after normalized to GAPDH. The higher ΔCt the more strand breaks. The P value is shown in the figure. SUPPLEMENT S1 Genes that were significantly UPREGULATED after folate intervention (by unadjusted paired t-test), list is sorted by P value Gene Symbol Nucleotide P VALUE Description OLFM4 NM_006418 0.0000 Homo sapiens differentially expressed in hematopoietic lineages (GW112) mRNA. FMR1NB NM_152578 0.0000 Homo sapiens hypothetical protein FLJ25736 (FLJ25736) mRNA. IFI6 NM_002038 0.0001 Homo sapiens interferon alpha-inducible protein (clone IFI-6-16) (G1P3) transcript variant 1 mRNA. Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 15 GALNTL5 NM_145292 0.0001 (GALNT15) mRNA. STIM2 NM_020860 0.0001 Homo sapiens stromal interaction molecule 2 (STIM2) mRNA. ZNF645 NM_152577 0.0002 Homo sapiens hypothetical protein FLJ25735 (FLJ25735) mRNA. ATP12A NM_001676 0.0002 Homo sapiens ATPase H+/K+ transporting nongastric alpha polypeptide (ATP12A) mRNA. U1SNRNPBP NM_007020 0.0003 Homo sapiens U1-snRNP binding protein homolog (U1SNRNPBP) transcript variant 1 mRNA. RNF125 NM_017831 0.0004 Homo sapiens ring finger protein 125 (RNF125) mRNA. FMNL1 NM_005892 0.0004 Homo sapiens formin-like (FMNL) mRNA. ISG15 NM_005101 0.0005 Homo sapiens interferon alpha-inducible protein (clone IFI-15K) (G1P2) mRNA. SLC6A14 NM_007231 0.0005 Homo sapiens solute carrier family 6 (neurotransmitter transporter) member 14 (SLC6A14) mRNA.
    [Show full text]
  • Sean Raspet – Molecules
    1. Commercial name: Fructaplex© IUPAC Name: 2-(3,3-dimethylcyclohexyl)-2,5,5-trimethyl-1,3-dioxane SMILES: CC1(C)CCCC(C1)C2(C)OCC(C)(C)CO2 Molecular weight: 240.39 g/mol Volume (cubic Angstroems): 258.88 Atoms number (non-hydrogen): 17 miLogP: 4.43 Structure: Biological Properties: Predicted Druglikenessi: GPCR ligand -0.23 Ion channel modulator -0.03 Kinase inhibitor -0.6 Nuclear receptor ligand 0.15 Protease inhibitor -0.28 Enzyme inhibitor 0.15 Commercial name: Fructaplex© IUPAC Name: 2-(3,3-dimethylcyclohexyl)-2,5,5-trimethyl-1,3-dioxane SMILES: CC1(C)CCCC(C1)C2(C)OCC(C)(C)CO2 Predicted Olfactory Receptor Activityii: OR2L13 83.715% OR1G1 82.761% OR10J5 80.569% OR2W1 78.180% OR7A2 77.696% 2. Commercial name: Sylvoxime© IUPAC Name: N-[4-(1-ethoxyethenyl)-3,3,5,5tetramethylcyclohexylidene]hydroxylamine SMILES: CCOC(=C)C1C(C)(C)CC(CC1(C)C)=NO Molecular weight: 239.36 Volume (cubic Angstroems): 252.83 Atoms number (non-hydrogen): 17 miLogP: 4.33 Structure: Biological Properties: Predicted Druglikeness: GPCR ligand -0.6 Ion channel modulator -0.41 Kinase inhibitor -0.93 Nuclear receptor ligand -0.17 Protease inhibitor -0.39 Enzyme inhibitor 0.01 Commercial name: Sylvoxime© IUPAC Name: N-[4-(1-ethoxyethenyl)-3,3,5,5tetramethylcyclohexylidene]hydroxylamine SMILES: CCOC(=C)C1C(C)(C)CC(CC1(C)C)=NO Predicted Olfactory Receptor Activity: OR52D1 71.900% OR1G1 70.394% 0R52I2 70.392% OR52I1 70.390% OR2Y1 70.378% 3. Commercial name: Hyperflor© IUPAC Name: 2-benzyl-1,3-dioxan-5-one SMILES: O=C1COC(CC2=CC=CC=C2)OC1 Molecular weight: 192.21 g/mol Volume
    [Show full text]
  • Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib
    Supplementary Online Content Chen G, McQuade JL, Panka DJ, et al. Clinical, molecular and immune analysis of dabrafenib-trametinib combination treatment for metastatic melanoma that progressed during BRAF inhibitor monotherapy: a phase 2 clinical trial. JAMA Oncology. Published online April 28, 2016. doi:10.1001/jamaoncol.2016.0509. eMethods. eReferences. eTable 1. Clinical efficacy eTable 2. Adverse events eTable 3. Correlation of baseline patient characteristics with treatment outcomes eTable 4. Patient responses and baseline IHC results eFigure 1. Kaplan-Meier analysis of overall survival eFigure 2. Correlation between IHC and RNAseq results eFigure 3. pPRAS40 expression and PFS eFigure 4. Baseline and treatment-induced changes in immune infiltrates eFigure 5. PD-L1 expression eTable 5. Nonsynonymous mutations detected by WES in baseline tumors This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/30/2021 eMethods Whole exome sequencing Whole exome capture libraries for both tumor and normal samples were constructed using 100ng genomic DNA input and following the protocol as described by Fisher et al.,3 with the following adapter modification: Illumina paired end adapters were replaced with palindromic forked adapters with unique 8 base index sequences embedded within the adapter. In-solution hybrid selection was performed using the Illumina Rapid Capture Exome enrichment kit with 38Mb target territory (29Mb baited). The targeted region includes 98.3% of the intervals in the Refseq exome database. Dual-indexed libraries were pooled into groups of up to 96 samples prior to hybridization.
    [Show full text]
  • Preview of “Supplement Table S4.Xls”
    Annotations for all recurrently lost regions cytoband 1p36.12 3p14.2 3q13.13 q value 0,01352 0,1513 0,085307 residual q value 0,01352 0,1513 0,085307 wide peak boundaries chr1:23457835-23714048 chr3:60396160-60637030 chr3:110456383-110657226 genes in wide peak E2F2 FHIT DPPA4 ID3 DPPA2 TCEA3 DDEFL1 TBC1D19 PI4K2B STIM2 GBA3 KCNIP4 DKFZp761B107 C4orf28 GPR125 FLJ45721 hsa-mir-218-1 CXCL3 GRSF1 HNRPD HTN1 HTN3 IBSP IGFBP7 IGJ IL8 CXCL10 KDR CXCL9 AFF1 MUC7 NKX6-1 PF4 PF4V1 PKD2 POLR2B PPEF2 PPAT PPBP PRKG2 MAPK10 PTPN13 REST CXCL6 CXCL11 CXCL5 SPINK2 SPP1 SRP72 STATH SULT1E1 UGT2B4 UGT2B7 UGT2B10 UGT2B15 UGT2B17 SPARCL1 VDP SLC4A4 HERC3 GENX-3414 CDKL2 TMPRSS11D ABCG2 ADAMTS3 CLOCK CEP135 G3BP2 HNRPDL ENAM FAM13A1 CXCL13 PAICS UGT2B11 HPSE NMU SMR3B NPFFR2 UGT2A1 CCNI hsa-mir-491 hsa-mir-31 4p15.32 4q13.1 4q13.1 (continued) 6q14.1 0,14888 0,17878 0,093693 0,14888 0,17878 0,093693 chr4:17969802-29966659 chr4:55756035-90966136 chr6:76830186-107898353 CCKAR AFM SEC31A AIM1 DHX15 AFP RUFY3 BCKDHB RBPSUH ALB WDFY3 PRDM1 SOD3 AMBN LPHN3 CCNC SLIT2 ANXA3 DKFZP564O0823 CGA SLC34A2 AREG RCHY1 CNR1 PPARGC1A ART3 ANKRD17 EPHA7 KIAA0746 BMP3 BRDG1 GABRR1 ANAPC4 BTC SMR3A GABRR2 SLA/LP CCNG2 ASAHL GRIK2 LGI2 SCARB2 COQ2 HTR1B TBC1D19 CDS1 SULT1B1 HTR1E PI4K2B CENPC1 TMPRSS11E IMPG1 STIM2 CSN1S1 MRPS18C ME1 GBA3 CSN2 COPS4 NT5E KCNIP4 CSN3 HSD17B11 PGM3 DKFZp761B107 DCK HERC5 POU3F2 C4orf28 DMP1 PLAC8 PREP GPR125 DSPP NUDT9 SIM1 FLJ45721 EPHA5 NUP54 ELOVL4 hsa-mir-218-1 EREG UGT2B28 MAP3K7 FGF5 ODAM TPBG GC HERC6 TTK GK2 SDAD1 RNGTT GNRHR UBE1L2 TBX18
    [Show full text]
  • The Hypothalamus As a Hub for SARS-Cov-2 Brain Infection and Pathogenesis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.08.139329; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The hypothalamus as a hub for SARS-CoV-2 brain infection and pathogenesis Sreekala Nampoothiri1,2#, Florent Sauve1,2#, Gaëtan Ternier1,2ƒ, Daniela Fernandois1,2 ƒ, Caio Coelho1,2, Monica ImBernon1,2, Eleonora Deligia1,2, Romain PerBet1, Vincent Florent1,2,3, Marc Baroncini1,2, Florence Pasquier1,4, François Trottein5, Claude-Alain Maurage1,2, Virginie Mattot1,2‡, Paolo GiacoBini1,2‡, S. Rasika1,2‡*, Vincent Prevot1,2‡* 1 Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, DistAlz, UMR-S 1172, Lille, France 2 LaBoratorY of Development and PlasticitY of the Neuroendocrine Brain, FHU 1000 daYs for health, EGID, School of Medicine, Lille, France 3 Nutrition, Arras General Hospital, Arras, France 4 Centre mémoire ressources et recherche, CHU Lille, LiCEND, Lille, France 5 Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and ImmunitY of Lille (CIIL), Lille, France. # and ƒ These authors contriButed equallY to this work. ‡ These authors directed this work *Correspondence to: [email protected] and [email protected] Short title: Covid-19: the hypothalamic hypothesis 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.06.08.139329; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Supplementary Table 1
    Supplementary Table 1. List of genes that encode proteins contianing cell surface epitopes and are represented on Agilent human 1A V2 microarray chip (2,177 genes) Agilent Probe ID Gene Symbol GenBank ID UniGene ID A_23_P103803 FCRH3 AF459027 Hs.292449 A_23_P104811 TREH AB000824 Hs.129712 A_23_P105100 IFITM2 X57351 Hs.174195 A_23_P107036 C17orf35 X51804 Hs.514009 A_23_P110736 C9 BC020721 Hs.1290 A_23_P111826 SPAM1 NM_003117 Hs.121494 A_23_P119533 EFNA2 AJ007292 No-Data A_23_P120105 KCNS3 BC004987 Hs.414489 A_23_P128195 HEM1 NM_005337 Hs.182014 A_23_P129332 PKD1L2 BC014157 Hs.413525 A_23_P130203 SYNGR2 AJ002308 Hs.464210 A_23_P132700 TDGF1 X14253 Hs.385870 A_23_P1331 COL13A1 NM_005203 Hs.211933 A_23_P138125 TOSO BC006401 Hs.58831 A_23_P142830 PLA2R1 U17033 Hs.410477 A_23_P146506 GOLPH2 AF236056 Hs.494337 A_23_P149569 MG29 No-Data No-Data A_23_P150590 SLC22A9 NM_080866 Hs.502772 A_23_P151166 MGC15619 BC009731 Hs.334637 A_23_P152620 TNFSF13 NM_172089 Hs.54673 A_23_P153986 KCNJ3 U39196 No-Data A_23_P154855 KCNE1 NM_000219 Hs.121495 A_23_P157380 KCTD7 AK056631 Hs.520914 A_23_P157428 SLC10A5 AK095808 Hs.531449 A_23_P160159 SLC2A5 BC001820 Hs.530003 A_23_P162162 KCTD14 NM_023930 Hs.17296 A_23_P162668 CPM BC022276 Hs.334873 A_23_P164341 VAMP2 AL050223 Hs.25348 A_23_P165394 SLC30A6 NM_017964 Hs.552598 A_23_P167276 PAQR3 AK055774 Hs.368305 A_23_P170636 KCNH8 AY053503 Hs.475656 A_23_P170736 MMP17 NM_016155 Hs.159581 A_23_P170959 LMLN NM_033029 Hs.518540 A_23_P19042 GABRB2 NM_021911 Hs.87083 A_23_P200361 CLCN6 X83378 Hs.193043 A_23_P200710 PIK3C2B
    [Show full text]
  • Us 2018 / 0305689 A1
    US 20180305689A1 ( 19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0305689 A1 Sætrom et al. ( 43 ) Pub . Date: Oct. 25 , 2018 ( 54 ) SARNA COMPOSITIONS AND METHODS OF plication No . 62 /150 , 895 , filed on Apr. 22 , 2015 , USE provisional application No . 62/ 150 ,904 , filed on Apr. 22 , 2015 , provisional application No. 62 / 150 , 908 , (71 ) Applicant: MINA THERAPEUTICS LIMITED , filed on Apr. 22 , 2015 , provisional application No. LONDON (GB ) 62 / 150 , 900 , filed on Apr. 22 , 2015 . (72 ) Inventors : Pål Sætrom , Trondheim (NO ) ; Endre Publication Classification Bakken Stovner , Trondheim (NO ) (51 ) Int . CI. C12N 15 / 113 (2006 .01 ) (21 ) Appl. No. : 15 /568 , 046 (52 ) U . S . CI. (22 ) PCT Filed : Apr. 21 , 2016 CPC .. .. .. C12N 15 / 113 ( 2013 .01 ) ; C12N 2310 / 34 ( 2013. 01 ) ; C12N 2310 /14 (2013 . 01 ) ; C12N ( 86 ) PCT No .: PCT/ GB2016 /051116 2310 / 11 (2013 .01 ) $ 371 ( c ) ( 1 ) , ( 2 ) Date : Oct . 20 , 2017 (57 ) ABSTRACT The invention relates to oligonucleotides , e . g . , saRNAS Related U . S . Application Data useful in upregulating the expression of a target gene and (60 ) Provisional application No . 62 / 150 ,892 , filed on Apr. therapeutic compositions comprising such oligonucleotides . 22 , 2015 , provisional application No . 62 / 150 ,893 , Methods of using the oligonucleotides and the therapeutic filed on Apr. 22 , 2015 , provisional application No . compositions are also provided . 62 / 150 ,897 , filed on Apr. 22 , 2015 , provisional ap Specification includes a Sequence Listing . SARNA sense strand (Fessenger 3 ' SARNA antisense strand (Guide ) Mathew, Si Target antisense RNA transcript, e . g . NAT Target Coding strand Gene Transcription start site ( T55 ) TY{ { ? ? Targeted Target transcript , e .
    [Show full text]
  • OR4D5 Sirna (H): Sc-96609
    SANTA CRUZ BIOTECHNOLOGY, INC. OR4D5 siRNA (h): sc-96609 BACKGROUND APPLICATIONS Olfactory receptors are G protein-coupled receptors that localize to the cilia OR4D5 siRNA (h) is recommended for the inhibition of OR4D5 expression in of olfactory sensory neurons where they display affinity for and bind to a vari- human cells. ety of odor molecules. The genes encoding olfactory receptors comprise the largest family in the human genome. The binding of olfactory receptor pro- SUPPORT REAGENTS teins to odor molecules triggers a signal transduction that propagates nerve For optimal siRNA transfection efficiency, Santa Cruz Biotechnology’s impulses throughout the body, ultimately leading to transmission of the sig- siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: nal to the brain and the subsequent perception of smell. OR4D5 (olfactory sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recom- receptor 4D5) is a 318 amino acid protein. The gene encoding OR4D5 maps mended. Control siRNAs or Fluorescein Conjugated Control siRNAs are to human chromosome 11. available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein REFERENCES Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and 1. Malnic, B., Hirono, J., Sato, T. and Buck, L.B. 1999. Combinatorial receptor sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, codes for odors. Cell 96: 713-723. sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238. 2. Glusman, G., Bahar, A., Sharon, D., Pilpel, Y., White, J.
    [Show full text]
  • INTRODUCING a NOVEL METHOD for GENETIC ANALYSIS of AUTISM SPECTRUM DISORDER Sepideh Nouri
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2013 INTRODUCING A NOVEL METHOD FOR GENETIC ANALYSIS OF AUTISM SPECTRUM DISORDER sepideh nouri Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Bioinformatics Commons, Computational Biology Commons, and the Genomics Commons Recommended Citation nouri, sepideh, "INTRODUCING A NOVEL METHOD FOR GENETIC ANALYSIS OF AUTISM SPECTRUM DISORDER" (2013). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 417. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/417 This Thesis (MS) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. INTRODUCING A NOVEL METHOD FOR GENETIC ANALYSIS OF AUTISM SPECTRUM DISORDER by Sepideh Nouri, M.S. APPROVED: Eric Boerwinkle, Ph.D., Supervisor Kim-Anh Do, Ph.D. Alanna Morrison, Ph.D. James Hixson, Ph.D. Paul Scheet, Ph.D. APPROVED: Dean, The University of Texas Graduate School of Biomedical Sciences at Houston INTRODUCING A NOVEL METHOD FOR GENETIC ANALYSIS OF AUTISM SPECTRUM DISORDER A THESIS Presented to the Faculty of The University of Texas Health Science Center at Houston and The University of Texas M.
    [Show full text]